• The European Medicines Agency accepted submission of a marketing authorization application for aripiprazole depot formulation by Otsuka Pharmaceutical Co. Ltd., of Tokyo, and H. Lundbeck A/S, of Copenhagen. The application is for once-monthly injection for maintenance treatment of adults with schizophrenia. It is designed for relapse prevention.